About
Technology
Issues
FAQ
Title
Abstract
Text
Figure Captions
Table Cells
Section Titles
Keywords
Subjects
Authors
From
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
2005
2004
2003
2002
2001
2000
1995
1990
1985
1980
1975
1970
1960
1950
1940
1930
1920
1910
1900
1850
1800
1700
1600
To
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
2005
2004
2003
2002
2001
2000
1995
1990
1985
1980
1975
1970
1960
1950
1940
1930
1920
1910
1900
1850
1800
1700
1600
All Types
Articles
Communications
Reviews
Discussions
Case Reports
Order By
Order By Year ASC
Order By Year DESC
Order By Citations ASC
Order By Citations DESC
Go
Profile
Top Authors
Prolific Authors
Top Journals
Main Disciplines
Main Topics
Most Cited Articles
Scientometrics
Avg Impact Factor
★★
Articles
★★★
Articles
exaly
›
Institutions
›
University of Texas MD Anderson Cancer Center
›
Department of Gynecologic Oncology and Reproductive Medicine
›
Top Articles
Department of Gynecologic Oncology and Reproductive Medicine
University of Texas MD Anderson Cancer Center
18.8K
Articles
720.6K
Citations
3.1
avg. Impact Factor
316
h-index
Most Cited Articles of Department of Gynecologic Oncology and Reproductive Medicine in 2022
Title
Journal
Year
Citations
Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma.
New England Journal of Medicine
2022
88
Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma.
New England Journal of Medicine
2022
30
Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer.
New England Journal of Medicine
2022
18
Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemia.
Leukemia
2022
15
Spatial transcriptomics of dorsal root ganglia identifies molecular signatures of human nociceptors.
Science Translational Medicine
2022
11
Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trial.
The Lancet Gastroenterology and Hepatology
2022
10
First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743.
Annals of Oncology
2022
10
Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity.
Cancer Cell
2022
10
A signature of saliva-derived exosomal small RNAs as predicting biomarker for esophageal carcinoma: a multicenter prospective study.
Molecular Cancer
2022
9
Evidence-Based Clinical Practice Guidelines for Extramammary Paget Disease.
JAMA Oncology
2022
7
Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281/LOGS): an international, randomised, open-label, multicentre, phase 2/3 trial.
Lancet, The
2022
7
Investigational antifungal agents for invasive mycoses: a clinical perspective.
Clinical Infectious Diseases
2022
6
PI3Kδ/γ inhibition promotes human CART cell epigenetic and metabolic reprogramming to enhance antitumor cytotoxicity.
Blood
2022
5
Prediction of biomarkers and therapeutic combinations for anti-PD-1 immunotherapy using the global gene network association.
Nature Communications
2022
5
Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study.
Lancet Oncology, The
2022
5
Clinical challenges treating infections: an update.
JAC-Antimicrobial Resistance
2022
5
Stromal HIF2 Regulates Immune Suppression in the Pancreatic Cancer Microenvironment.
Gastroenterology
2022
5
Co-targeting of BAX and BCL-XL proteins broadly overcomes resistance to apoptosis in cancer.
Nature Communications
2022
5
Clinically translatable cytokine delivery platform for eradication of intraperitoneal tumors.
Science Advances
2022
5
Mutational Activation of the NRF2 Pathway Upregulates Kynureninase Resulting in Tumor Immunosuppression and Poor Outcome in Lung Adenocarcinoma
Cancers
2022
5
Clear cell carcinoma of the endometrium.
Gynecologic Oncology
2022
4
Myocardial Rev-erb-Mediated Diurnal Metabolic Rhythm and Obesity Paradox.
Circulation
2022
4
Phase I/II trial of encorafenib, cetuximab, and nivolumab in patients with microsatellite stable, BRAFV600E metastatic colorectal cancer.
Journal of Clinical Oncology
2022
4
Impact of early palliative care according to baseline symptom severity: Secondary analysis of a cluster-randomized controlled trial in patients with advanced cancer.
Cancer Medicine
2022
4
Utilization of Immunotherapy for the Treatment of Hepatocellular Carcinoma in the Peri-Transplant Setting: Transplant Oncology View.
Cancers
2022
4
Schools/Departments
The list of schools/departments is not comprehensive since it is common to drop the department in the affiliation.
site/software ©
exaly
; All materials licenced under
CC by-SA
.